Loading…
← CockpitCompetitor Analysis › 688321.SS Shenzhen Chipscreen Biosciences Co. Ltd. Class AOpen in the cockpit ↗

Shenzhen Chipscreen Biosciences Co. Ltd. Class A688321.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Shenzhen biotech that discovers original small-molecule drugs, known for its HDAC-inhibitor lymphoma drug chidamide.

≈ A small, China-only IncyteMomentum laggard 9
Mkt cap
$1.18B
US dollars, full cap
Free float
62%
of shares outstanding
$/day
$21.3M
20-day average traded
Fwd P/E
60.4×
forward earnings
ROIC−WACC
-4.6 pp
WACC 9.5%
Hurdle
n/a
no reverse DCF
Next earnings
133 days
31 Mar 2027
Close · CNYCN¥18.74
1D-1.9%
1W-12.2%
1M-16.3%
3M-39.9%
6M-38.0%
YTD-35.9%
1Y-39.0%
ATR %4.7%
52w lowhigh48.6% off high

What Shenzhen Chipscreen Biosciences does

Shenzhen biotech that discovers original small-molecule drugs, known for its HDAC-inhibitor lymphoma drug chidamide.

Sells its own patented drugs mainly to hospitals, so a drug's place on China's national reimbursement list is what turns approval into volume. Its lymphoma drug has also been licensed to partners for markets outside China.

In one line: A small, China-only Incyte.

Products and services

  • Chidamide (Epidaza) HDAC inhibitor
  • Chiglitazar diabetes PPAR agonist
  • Earlier-stage oncology pipeline

Customers

  • Hospitals and oncology centers

Where it sits in the supply chain

  • Pharmaceuticals
  • Innovative biotech
  • Oncology and metabolic small molecules

What could go right

  • Label expansions into new cancer types
  • National reimbursement listing

What could go wrong

  • Clinical trial failure risk
  • Reimbursement price cuts

Moat: narrow (IP / patents). Patent-protected first-in-class molecules discovered in-house rather than licensed-in generics.

Headquarters: Shenzhen, China · Founded: 2001 · Employees: 1,002

Named competitors

Shenzhen Chipscreen Biosciences at a glance

Size Shenzhen Chipscreen Biosciences (688321.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.18B, the 1864th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥18.74 on 18 Nov 2026.

Performance Over six months the shares fell 38.0%, against -17.3% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.

Growth Revenue grew 26.8% over the last twelve months (peer median -1.5%); the operating margin is 11.7% (peer median -13.3%).

Valuation It trades at 60.4× forward earnings against a peer median of 18.6× (2nd most expensive of 10).

Capital Return on invested capital runs 4.6 points below its cost of capital (9.5% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 85688321.SS 65
Six months, rebased to 100: Shenzhen Chipscreen Biosciences against the median of its 20 peers (local-currency closes).

Shenzhen Chipscreen Biosciences financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.08BCN¥908MCN¥656MCN¥516MCN¥528M
Revenue growth—+38%+27%-2%—
Gross profitCN¥969MCN¥765MCN¥544MCN¥434MCN¥475M
EBITDAn/aCN¥155MCN¥899,100-CN¥138MCN¥48.3M
Net incomeCN¥71.4MCN¥51.0M-CN¥115MCN¥88.8MCN¥17.5M
Free cash flow-CN¥134M-CN¥62.8M-CN¥179M-CN¥372M-CN¥351M
Capital expenditureCN¥321MCN¥179MCN¥268MCN¥229MCN¥400M
Total debtCN¥1.46BCN¥1.67BCN¥1.46BCN¥1.20BCN¥1.05B

Quarterly statements and history in the cockpit →

Shenzhen Chipscreen Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%0%688443NKTR68556880620009893000062616HROW347850IDIA3000264547002550AVLNGPCRCMHC000950688076GHRS688321.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shenzhen Chipscreen Biosciences is the large dot.

Fundamentals: revenue growth against valuation

-50%-25%0%+25%+50%0×200×400×000989HROW3000264547002550CMHC688076688321.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shenzhen Chipscreen Biosciences is the large dot.

Shenzhen Chipscreen Biosciences competitors and peer comparison

Head to head with its named competitors (688321.SS vs 600276.SS vs 688235.SS vs 0013.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shenzhen Chipscreen Biosciences 688321.SS$1.18B-38%+27%12%60.4×n/a
Jiangsu Hengrui Pharmaceuticals 600276.SS$45.7B-13%+6%27%33.4×13.4%
BeOne Medicines 688235.SS$45.5B+9%+25%18%59.7×19.1%
HUTCHMED (China) 0013.HK$2.38B+14%-9%-6%35.9×47.0%

How Shenzhen Chipscreen Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shenzhen Chipscreen Biosciences against its 20 peers (data as of 18 Nov 2026)
Measure688321.SSPeer medianRank in peer set
1-month return-16.3%-4.9%4th lowest of 21
6-month return-38.0%-17.3%5th lowest of 21
Distance from 52-week high-48.6%-39.3%8th lowest of 21
Revenue growth (TTM)+26.8%-1.5%5th highest of 18
Operating margin11.7%-13.3%4th highest of 18
Forward P/E60.4×18.6×2nd most expensive of 10
ROIC minus cost of capital-4.6 pp-8.6 pp8th highest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%60.4×n/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%n/an/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%n/an/an/a
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%n/an/an/a
Mabwell (Shanghai) Bioscience 688062.SSChina$1.20B-46%+15%-129%n/an/an/a
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%22.1×-4.0%-9.0%
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%n/a44.1%-13.2%
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%n/an/an/a
Harrow HROWUnited States$1.21B+4%+21%1%26.8×n/an/a
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%n/an/an/a
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%n/an/an/a
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%21.3×7.0%-5.3%
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%14.5×n/an/a
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%18.4×3.4%-1.2%
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
Cosmo CMHC.SWSwitzerland$1.13B-30%-45%-13%418.7×n/an/a
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%18.6×n/an/a
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%11.9×3.4%+27.9%
GC Biopharma 006280.KSSouth Korea$1.12B-10%-3%4%4.6×n/an/a
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a

Questions

Who are Shenzhen Chipscreen Biosciences's main competitors?
Named competitors: Hengrui Medicine (600276.SS), BeiGene (688235.SS), Hutchmed (0013.HK). The cockpit's measured peer set (industry) also includes Chongqing Genrix Biopharmaceutical (688443.SS), Nektar Therapeutics (NKTR), Ascentage Pharma Group International (6855.HK), Mabwell (Shanghai) Bioscience (688062.SS), Jiuzhitang (000989.SZ), Chongqing Lummy Pharmaceutical (300006.SZ).
Is Shenzhen Chipscreen Biosciences expensive compared with its peers?
On forward p/e it trades at 60.4× against a peer median of 18.6×, 2nd most expensive of 10 in its peer set.
How has Shenzhen Chipscreen Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned -38.0% against -17.3% for the median peer; over one year -39.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.